Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

BACKGROUND: Immune checkpoint inhibitors (ICIs) have been approved as second‐line therapy for advanced non–small cell lung cancers (NSCLCs) progressing after platinum‐based chemotherapy. However, some patients' disease progressed rapidly and sometimes exhibited explosive tumor progression. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergnenegre, Alain, Geier, Margaux, Guisier, Florian, Lamy, Regine, Comet, Bénédicte, Le Garff, Gwenaelle, Do, Pascal, Janicot, Henri, Morel, Hugues, Decroisette, Chantal, Andre, Michel, Falchero, Lionel, Paleiron, Nicolas, Monnet, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970062/
https://www.ncbi.nlm.nih.gov/pubmed/31747137
http://dx.doi.org/10.1002/cam4.2716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970062/
https://www.ncbi.nlm.nih.gov/pubmed/31747137
http://dx.doi.org/10.1002/cam4.2716

Ejemplares similares